Loading presentation...

Present Remotely

Send the link below via email or IM


Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.


HCV Vaccine

No description

Mohamed Nosser

on 28 April 2015

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of HCV Vaccine

Structure of HCV
enveloped group virus
Positive sense , ssRNA
Is a vaccine necessary ?
Yes ,
Marked reduction in HCV incidence
limitation of current therapy :
- Reinfection.
- Cost.
- Side effect.

Clinical trials are ongoing and treatment will be soon available. day by day, hope becomes actually more tangible
Structure of HCV .
Is a vaccine necessary ?
Why there is no vaccine yet ?
The role of Humoral and Cell-Mediated Immune Responses
Trials for an effective vaccine .
codes for structural proteins (core,E1,E2)
codes for non-structural proteins (NS1:NS5B)
Why there is no vaccine yet ?
Genomic variability of HCV.
Escaping from neutralization:
The shielding of neutralizing epitopes by glycosylation of defined amino acids of envelope glycoprotein.
The association of HCV with serum factors such as LDL and very low-density lipoprotein (VLDL).
Adenoviral based vaccine of HCV

Elicit HCV-specific T cells .

Two adenoviral vectors expressing NS and core proteins from HCV genotype 1b were constructed based on rare serotypes

T cell responses targeted multiple proteins and were capable of recognizing heterologous strains and could be sustained for at least a year after boosting with the heterologous adenoviral vector.

The hepatitis C first ‘prime’ vaccine is based on a chimpanzee adenovirus called ChAd3.

The second ‘boost’ vaccine – a modified vaccine Ankara (MVA) virus.

Neither the adenovirus nor MVA is able to replicate, so they packaged up inside can’t cause a hepatitis C infection either.


Woodland, D. L. (2004). Jump-starting the immune system: prime–boosting comes of age. Trends in immunology, 25(2), 98-104.‏
INO-8000 / VGX-6150 Vaccine

Inovio Pharmaceuticals.

Phase 1 synthetic multi-antigen DNA immunotherapy.

Inovio's SynCon design is intended to provide broader protection against new mutations of a virus.

Covering hepatitis C virus (HCV) genotypes 1a and 1b.

Consists of three plasmid DNAs and an adjuvant plasmid expressing IL-28B.

Target NS3, NS4A, NS4B and NS5A.

The vaccine is delivered via the Cellectra® electroporation delivery device.

Tested in chronically infected patients who have previously failed standard drug therapy.

The role of Humoral and Cell-Mediated Immune Responses

Prepared by :

Mohamed Nosser , Sara Hamouda,



Faculty of Pharmacy
Tanta University

Under supervision of :

Dr/ Fotouh Rashed Mansour

A new promising vaccine
for HCV
Full transcript